CAESAREA, Israel, Feb. 15,
2024 /PRNewswire/ -- IceCure Medical Ltd.
(Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the
ProSense® System, a minimally-invasive cryoablation technology that
destroys tumors by freezing as an alternative to surgical tumor
removal, today announced Eisuke
Fukuma, MD, PhD, who has performed over 600 breast
cryoablation procedures with ProSense®, will host events that
feature ProSense® at two upcoming medical conferences in
Japan. Dr. Fukuma is Chair, Breast
Center, Kameda Medical Center, and President of the 8th
International Oncoplastic Breast Surgery Symposium.
- 30th Japan Breast Disease Society
February 16-17, 2024
Kadema Medical Center, Okinawa,
Japan
The event will be attended by Japanese doctors.
- 8th International Oncoplastic Breast Surgery
Symposium
February 26-27,
2024
Chiba, Japan
This event will be attended by 25 breast surgery experts from
Asia, the U.S., and Europe, who are thought leaders in their
respective countries.
Educational sessions at the breast conferences will focus on
nonsurgical tumor ablation and will include clinical data,
indication-specific information, pathology analysis, and more.
"We are very grateful to Dr. Fukuma for leading educational
events and sharing with other doctors his vast experience using
ProSense® to help women achieve better outcomes," stated
IceCure CEO Eyal Shamir. "The number
of ProSense® user-initiated educational events and published
studies is generating increasing momentum for the adoption and
wider use of cryoablation globally."
Dr. Fukuma commented, "I'm always pleased to engage with my
colleagues in Japan and
internationally to share my insight and long-term experience with
cryoablation. I've used ProSense® with hundreds of breast
cancer patients, who have had excellent efficacy and safety
outcomes. Based on my first-hand experience as well as published
studies, there is no reason why cryoablation should not be the
standard of care in early-stage breast cancer."
Dr. Dennis Holmes, a breast
cancer surgeon and key opinion leader with over 50 peer reviewed
journal publications of his innovative work, commented, "My mission
as a breast cancer surgeon and cancer researcher is to raise the
standard of care. Using ProSense®️ for breast cancer cryoablation
is part of my practice and an essential part of oncoplastic
surgery, which combines breast conserving procedures with plastic
surgical techniques to optimize results. I was pleased to
participate in the educational session at the Oncoplastic Breast
Surgery Symposium in Japan with
Dr. Fukuma. It is only through innovation that we can continually
improve the effectiveness, safety, and quality of breast cancer
care for the benefit of those affected by the diagnosis."
ProSense® is currently pending regulatory approval in
Japan.
About ProSense®
The ProSense® Cryoablation System provides a minimally invasive
treatment option to destroy tumors by freezing them. The system
uniquely harnesses the power of liquid nitrogen to create large
lethal zones for maximum efficacy in tumor destruction in benign
and cancerous lesions, including breast, kidney, lung, and
liver.
ProSense® enhances patient and provider value by accelerating
recovery, reducing pain, surgical risks, and complications. With
its easy, transportable design and liquid nitrogen utilization,
ProSense® opens that door to fast and convenient office-based
procedure for breast tumors.
About IceCure Medical
IceCure Medical (Nasdaq: ICCM) develops and markets ProSense®,
an advanced liquid-nitrogen-based cryoablation therapy for the
treatment of tumors (benign and cancerous) by freezing, with the
primary focus areas being breast, kidney, bone and lung cancer. Its
minimally invasive technology is a safe and effective alternative
to hospital surgical tumor removal that is easily performed in a
relatively short procedure. The system is marketed and sold
worldwide for the indications cleared and approved to date
including in the U.S., Europe, and
China.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995 and other Federal
securities laws. Words such as "expects," "anticipates," "intends,"
"plans," "believes," "seeks," "estimates" and similar expressions
or variations of such words are intended to identify
forward-looking statements. For example, IceCure is using forward
looking statement in this press release when it discusses:
ProSense's features at two upcoming medical conferences in
Japan, the expected number of
attendees at the conferences, the expected focus of the
conferences, the belief that innovation can continually improve the
effectiveness, safety, and quality of breast cancer care.
Historical results of scientific research and clinical and
preclinical trials do not guarantee that the conclusions of future
research or trials will suggest identical or even similar
conclusions. Important factors that could cause actual results,
developments and business decisions to differ materially from those
anticipated in these forward-looking statements include, among
others: the Company's planned level of revenues and capital
expenditures; the Company's available cash and its ability to
obtain additional funding; the Company's ability to market and sell
its products; legal and regulatory developments in the United States and other countries; the
Company's ability to maintain its relationships with suppliers,
distributors and other partners; the Company's ability to maintain
or protect the validity of its patents and other intellectual
property; the Company's ability to expose and educate medical
professionals about its products; political, economic and military
instability in the Middle East,
specifically in Israel; as well as
those factors set forth in the Risk Factors section of the
Company's Annual Report on Form 20-F for the year ended
December 31, 2022 filed with the SEC
on March 29, 2023, and other
documents filed with or furnished to the SEC which are available on
the SEC's website, www.sec.gov. The Company undertakes no
obligation to update these statements for revisions or changes
after the date of this release, except as required by law.
IR Contact:
Email: investors@icecure-medical.com
Michael Polyviou
Phone: 732-232-6914
Todd Kehrli
Phone: 310-625-4462
Logo -
https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/icecures-prosense-to-be-featured-at-two-upcoming-medical-conferences-in-japan-302062914.html
SOURCE IceCure Medical